NGM Biopharmaceuticals
South San Francisco
About NGM Biopharmaceuticals
NGM Biopharmaceuticals is a privately-held drug discovery company committed to identifying transformational medicines that dramatically improve human health. Based on emerging human clinical and genetic observations, the company has devised several innovative experimental approaches to discover new therapies for the treatment of metabolic and cardiovascular diseases. The company's current focus is on the gastrointestinal endocrine system, with an aim to identify novel factors implicated in the pathogenesis of type 2 diabetes and the apparent resolution of this grievous disease in patients who have undergone gastric bypass surgery.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Total funding: $542.4M
- Funding stage: IPO
- Last round: Series A (Jul 2024)
- Ticker: nasdaq:NGM
- Website: ngmbio.com
- Phone: 6505831646
Industries & Categories
Biopharma, Biotechnology, Genetics, Medical
Social Profiles
Canonical: https://fsome.com/organization/ngm-biopharmaceuticals-121241 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.